Therapeutic cancer vaccines revamping: technology advancements and pitfalls.

Détails

ID Serval
serval:BIB_60856EC0D50D
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Therapeutic cancer vaccines revamping: technology advancements and pitfalls.
Périodique
Annals of oncology
Auteur⸱e⸱s
Antonarelli G., Corti C., Tarantino P., Ascione L., Cortes J., Romero P., Mittendorf E.A., Disis M.L., Curigliano G.
ISSN
1569-8041 (Electronic)
ISSN-L
0923-7534
Statut éditorial
Publié
Date de publication
12/2021
Peer-reviewed
Oui
Volume
32
Numéro
12
Pages
1537-1551
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Cancer vaccines (CVs) represent a long-sought therapeutic and prophylactic immunotherapy strategy to obtain antigen (Ag)-specific T-cell responses and potentially achieve long-term clinical benefit. However, historically, most CV clinical trials have resulted in disappointing outcomes, despite promising signs of immunogenicity across most formulations. In the past decade, technological advances regarding vaccine delivery platforms, tools for immunogenomic profiling, and Ag/epitope selection have occurred. Consequently, the ability of CVs to induce tumor-specific and, in some cases, remarkable clinical responses have been observed in early-phase clinical trials. It is notable that the record-breaking speed of vaccine development in response to the coronavirus disease-2019 pandemic mainly relied on manufacturing infrastructures and technological platforms already developed for CVs. In turn, research, clinical data, and infrastructures put in place for the severe acute respiratory syndrome coronavirus 2 pandemic can further speed CV development processes. This review outlines the main technological advancements as well as major issues to tackle in the development of CVs. Possible applications for unmet clinical needs will be described, putting into perspective the future of cancer vaccinology.
Mots-clé
COVID-19, Cancer Vaccines/therapeutic use, Humans, Neoplasms/therapy, SARS-CoV-2, Technology, cancer, immunotherapies, vaccines
Pubmed
Open Access
Oui
Création de la notice
21/09/2021 14:13
Dernière modification de la notice
04/12/2021 7:37
Données d'usage